Patients with bipolar disorder experienced significant reductions in sleep efficiency, which was not the case in patients with schizophrenia, although effect sizes for bipolar disorder were smaller overall.
Researchers explored the genetic correlation between schizophrenia and osteoporosis.
The study confirmed a continuation of the trend for elevated placebo response and reduced treatment effect in clinical trials of schizophrenia medications.
Dr. Reddy’s Laboratories announced the launch of Ziprasidone Mesylate for Injection, the generic equivalent of Geodon for Injection (Pfizer).
Together with cognitive impairment and eye movement abnormalities, diminished EEG response appears to form a neurobiological “fingerprint” for negative symptoms in psychosis.
In patients with schizophrenia, cannabis use may be linked to elevated risk of all-cause mortality but decreased risk of mortality from digestive organ diseases.
Infections raised the risk for substance-induced psychosis, with the risk doubled for the first 2 years. The largest increase in risk was observed for hepatitis.
Roughly two-thirds of patients categorized their experience with antipsychotics as more negative than positive and 34.9% endorsed an “extremely negative” experience.
Connectivity was significantly higher in nonrecovered than recovered patients, and there were fewer connections in recovered patients compared with nonrecovered patients, indicating significant differences in network structure.
Working memory is impaired in schizophrenia, and epigenetic mechanisms such as DNA methylation may contribute to illness risk.